Glass bead flow rates to facilitate immunodiagnostic test element manufacture
10107809 ยท 2018-10-23
Assignee
Inventors
- Jonathan Burr Crowther (Stanton, NJ, US)
- Amy Louise Surowitz (Three Bridges, NJ, US)
- Anna Krystyna Luczak (Parlin, NJ, US)
Cpc classification
Y10T436/25
GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10T29/49982
GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
International classification
G01N33/00
PHYSICS
G01N33/53
PHYSICS
Abstract
A method is provided for of preparing a glass bead mixture using inert nanoparticles to improve flow rates of the glass beads for purposes of manufacturing an immunodiagnostic test element, such as a column agglutination test cassette. The immunodiagnostic test element includes a plurality of test columns including an aqueous reagent in each test column.
Claims
1. A method for manufacturing and using an immunodiagnostic test element having a plurality of test columns provided on a planar substrate, each of the test columns having an open upper end, the method comprising the steps of: washing a plurality of glass beads; placing the plurality of washed glass beads in a mixing apparatus; placing a quantity of inert nanoparticles in the mixing apparatus, in which the glass beads and the nanoparticles include the same material; mixing together the plurality of glass beads and the inert nanoparticles using the mixing apparatus, such that the inert nanoparticles adhere to the exterior of said beads; flowing the mixed glass beads and inert nanoparticles from the mixing apparatus into at least one test column of the immunodiagnostic test element; adding an aqueous reagent to the at least one test column, the aqueous reagent causing the inert nanoparticles to dissociate from the glass beads; and conducting a test using the immunodiagnostic test element by adding a sample to the at least one test column, and centrifuging the immunodiagnostic test element to create an agglutination reaction wherein formed agglutinates are caused to flow from an upper portion of the at least one test column through the glass beads toward the bottom of the at least one test column.
2. The method according to claim 1, wherein the plurality of glass beads each comprise at least about 85% SiO.sub.2.
3. The method according to claim 2, wherein the plurality of glass beads comprise borosilicate glass beads comprising a size of between about 50-120 m diameter.
4. The method according to claim 3, wherein the plurality of glass beads comprise borosilicate glass beads comprising a size of between about 65-90 m diameter.
5. The method according to claim 4, wherein the plurality of glass beads comprise borosilicate glass beads comprising a size of between about 75-90 m diameter.
6. The method according to claim 1, wherein the step of placing inert nanoparticles in the mixing apparatus comprises placing an amount of nanoparticles equivalent to about 0.0001% to about 1.0% by weight as between the inert nanoparticles and the glass beads.
7. The method according to claim 6, wherein the step of placing inert nanoparticles in the mixing apparatus comprises placing an amount of nanoparticles equivalent to about 0.0005% to about 0.1% by weight as between the inert nanoparticles and the glass beads.
8. The method according to claim 7, wherein the step of placing inert nanoparticles in the mixing apparatus comprises placing an amount of nanoparticles equivalent to about 0.0005% to about 0.0015% by weight as between the inert nanoparticles and the glass beads.
9. The method according to claim 1, wherein the step of placing inert nanoparticles in the mixing apparatus comprises placing nanoparticles having an agglomerate size equivalent to about 1 m.
10. The method according to claim 9, wherein the inert nanoparticles comprise at least about 99% or more SiO.sub.2.
11. The method according to claim 9, wherein the step of mixing together the plurality of glass beads and the inert nanoparticles includes reducing the size of the inert nanoparticles to between about 0.1 to 0.2 m in aggregate, each aggregate comprised of a plurality of primary particles.
12. The method according to claim 1, wherein the step of washing comprises using an acid wash, or a combination of a caustic wash and an acid wash.
13. A method for improving flowability of glass beads in an immunodiagnostic test element, said test element including a plurality of test columns, the immunodiagnostic test element being used to perform agglutination reactions of an applied sample using column agglutination technology, said method comprising: washing a plurality of the glass beads; placing the plurality of glass beads in a mixing apparatus; placing a preselected quantity of inert nanoparticles in the mixing apparatus in which the glass beads and the nanoparticles include the same material; mixing together the plurality of glass beads and the inert nanoparticles using the mixing apparatus, wherein the inert nanoparticles are caused to adhere to the exterior surface of said glass beads; flowing the mixture of the glass beads and the inert nanoparticles from the mixing apparatus into the test columns of the immunodiagnostic test element; and placing an aqueous reagent into the test columns in which the aqueous reagent causes the inert nanoparticles to dissociate from the glass beads.
14. The method according to claim 13, further comprising securing the plurality of test columns in parallel in a rigid package.
15. The method according to claim 13, wherein the step of placing a preselected quantity of inert nanoparticles in the mixing apparatus comprises placing fumed silica in the mixing apparatus at about 0.0001% to about 1.0% by weight as between the fumed silica and the glass beads.
16. The method according to claim 15, wherein the step of placing a preselected quantity of inert nanoparticles in the mixing apparatus comprises placing fumed silica in the mixing apparatus at about 0.0005% to about 0.1% by weight as between the fumed silica and the glass beads.
17. The method according to claim 16, wherein the step of placing a preselected quantity of inert nanoparticles in the mixing apparatus comprises placing fumed silica in the mixing apparatus at about 0.0005% to about 0.0015% by weight as between the fumed silica and the glass beads.
18. The method according to claim 13, wherein the plurality of glass beads comprise borosilicate glass beads having a diameter of between about 50-120 m.
19. The method according to claim 18, wherein the plurality of glass beads comprise borosilicate glass beads having a diameter of between about 65-90 m.
20. The method according to claim 19, wherein the plurality of glass beads comprise borosilicate glass beads having a diameter of between about 75-90 m.
21. The method according to claim 15, wherein the inert nanoparticles adhered to the exterior surface of said glass beads comprise fumed silica particles fused into aggregates having a size of about 0.1 m to about 0.2 m.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
DETAILED DESCRIPTION
(5) Throughout the following discussion, several terms such as outer, inner, top, bottom, above and below are used in order to provide a suitable frame of reference with regard to the accompanying drawings.
(6) The term sample means a volume of a liquid, solution or suspension, intended to be subjected to qualitative or quantitative determination of any of its properties, such as the presence or absence of a component, the concentration of a component, etc. The embodiments of the present invention are applicable to human and animal samples of whole blood. Typical samples in the context of the present invention as described herein include blood, plasma, red blood cells, serum and suspension thereof.
(7) The term about as used in connection with a numerical value throughout the description and claims denotes an interval of accuracy, familiar and acceptable to a person skilled in the art. The interval governing this term is preferably 10%. Unless specified, the terms described above are not intended to narrow the scope of the invention as described herein and according to the claims.
(8) Referring to the drawings,
(9) When testing a blood sample 105, a quantity of a patient's blood sample 105 is dispensed in each of the test columns 103 through art opening in the top of the columns 103. The test element 101 is then centrifuged or vertically agitated to produce mixing of the sample and agglutination reagent. While being spun by the centrifuge 106, the blood descends to varying levels, based upon the size of the formed agglutinants, through the glass beads 102 and the aqueous reagent 104, as driven by the applied g forces. Depending on agglutination of the blood sample 105 in the aqueous reagent 104, all or portions of the blood sample may not pass through the glass beads 102. Agglutinated cells 109 do not pass entirely through the glass beads, while non-agglutinated red blood cells 108 continue to pass between the beads 102 and eventually sink to the bottom of the test column 103. Depending on the amount of agglutination, agglutinants may become trapped in the glass beads 102 at various levels. The characteristic agglutination pattern of the blood sample determines the reaction result of the sample 105 using a conventional agglutination pattern metric 110 for comparison. In this manner, the glass heads 102 act as a filter to the passage of blood therethrough based on agglutination properties of the blood sample and facilitate inspection so as to determine the extent of the reaction, either visually or by instrument vision.
(10) As noted above and in order to achieve efficient filling of the test columns 103 of the herein described test element 101 with glass beads, it is desirable to maintain uniform flow properties of the glass beads 102 from batch to batch manufacture.
(11) As an initial step, the unwashed glass beads can be tested for flow rates and other properties even though the wash process has yet to be performed. This test step can help to insure that the beads will flow at an adequate rate after the steps of washing the glass beads and adding nanoparticles to the glass beads, as will be described below. Other quality control requirements for incoming glass heads can include, for example, a minimal amount of discolored heads through visual inspection or other means, a minimum requirement for spherical conformity, as well as verification of a specified range of particle sizes, and a maximum amount of particular contaminants.
(12) The presence of contaminants and/or impurities on the surfaces of the glass beads can cause the blood cells to adhere to the beads and impact functionality and consistency of the test element. For example, soda ash and oils may appear on the surface of glass beads as a byproduct of their manufacture. To remove these and other contaminants from the surface of the supplied glass beads, an exemplary acid wash is performed at step 202, including rinsing the glass beads in distilled water. An alternative additional wash can be performed which includes a caustic wash, before or after the acid wash, and a rinse step using distilled water. At step 203, the washed beads are dried in an oven. It should be noted that the caustic and acid washes, and the drying step, are well known and familiar to those having ordinary skill in the art. These cleaning steps are not essential to the present invention and may be replaced with equally effective cleaning and drying procedures. Such other procedures are considered to be equivalent and interchangeable substitutes for the washing and drying steps described herein and included in the claims below. At step 204, the glass beads are screened or sifted to separate any residual clumps.
(13) At step 205, the glass beads are then tested for flow rates using a Hall Flow meter, which is a standardized calibrated steel funnel, or a similar apparatus. At this point, a minimum flow rate may be required depending on manufacturing processes, in particular, on the tools used for filling the column agglutination test element 101. To increase consistency of flow rates for beads across batches, the batches that have undergone the preparation steps described above can be categorized according to their measured flow rates. To achieve consistency in flow rates across batches, they can be mixed together. For example, two batches can be placed in an appropriately sized container and manually mixed using a spoon or the two batches can be flowed through a sieve.
(14) At step 206, inert nanoparticles are blended with the washed glass beads to improve the flow rates of the washed glass beads. According to the present embodiment, hydrophilic fumed silica is utilized, comprising about 99% or more SiO.sub.2 by weight, formed as chained agglomerates of spherical SiO.sub.2 particles. Fumed silica is a common commercial product available from several manufacturers, for example, Evonik Degussa Corporation, Cabot Corporation, Wacker Chemie-Dow Corning, and others. More specifically, and in accordance with one embodiment, the Aerosil 380 brand of fumed silica is used as the source of nanoparticles blended with the glass beads.
(15) Still referring to step 206, the blending of the glass beads and fumed silica can be performed according to the following embodiment, as an example. A predetermined quantity of glass beads, e.g., about 20 kg, is placed in a Patterson-Kelley V-blender. A small amount of fumed silica particles, e.g., about 0.2 g, is added to the V-blender and the V-blender is then run for about three minutes at about 24 revolutions per minute (RPM). This step allows the fumed silica nanoparticles to substantially and uniformly blend with the glass beads. The amount of added fumed silica is preferably about 0.0001% to about 1.0% by weight, more preferably about 0.0005% to about 0.1% by weight, and even more preferably about 0.0005% to about 0.0015% by weight, which provides adequate glass bead flow rates during test element manufacture.
(16)
(17) Based on the above described blending of inert nanoparticles with the glass beads, a significant increase in flow rates is provided. Referring to
(18)
(19) Following the column fill operation when aqueous agglutination reagent and the glass beads/nanoparticles are dispensed in each of the test columns as part of the test element manufacture, the attractive forces created between the fumed silica particles and the glass beads are easily diffused and the nanoparticles separate into solution. As a result, the nanoparticles permit adequate flow rates to be maintained during the fill procedure but do not interfere with the remainder of test element manufacture or intended test protocol clue to their small relative size.
PARTS LIST FOR FIGS. 1-4
(20) 100 application of glass beads with added nanoparticles 101 test element 102 glass beads 103 test columns 104 aqueous reagent 105 blood sample 106 centrifuge 107 poured glass beads 108 descended blood sample 109 undescended blood sample 110 column agglutination reactions 111 substrate 112 linear array 201 stepreceive glass beads 202 stepwash glass beads 203 stepdry glass beads 204 stepscreen beads 205 steptest and mix glass beads 206 stepblend glass beads with fumed silica 301 washed glass bead 302 mixing of glass beads and fumed silica 303 glass bead with adhered nanoparticles 304 glass bead surface contact 305 glass bead surfaces separated by nanoparticles 306 nanoparticle agglomerates 307 nanoparticle aggregates
(21) This written description uses examples to disclose the invention, including the best mode, and also to enable any person skilled in the art to practice the invention, including making and using any apparatus or system and performing any incorporated methods. The patentable scope of the invention is defined by the claims below, and may include other examples that are practiced by those skilled in the art. Such other examples are intended to be within the scope of the claims below if they have structural elements that do not differ from the literal language of the claims, or if they include equivalent structural elements with insubstantial differences from the literal language of the claims.